Release Date: 12/09/2016

In the fight against leukemia, TG Therapeutics is conducting two research studies for the treatment of Chronic Lymphocytic Leukemia (CLL) and Anthony G. Thomas, DO, chief of hematology/oncology at Memorial Hospital, a Care New England facility, is currently recruiting patients for these studies to investigate their efficiency and progression-free survival.

The studies include:

• The Genuine Study, a Phase 3 clinical trial for high-risk CLL patients who have been previously treated. The trial utilizes a new anti-CD20 antibody (ublituximab) with the approved oral BTK inhibitor (Ibrutinib) or Ibutinib alone.

• The Unity Study, a Phase 3 clinical trial for newly diagnosed and previously treated patients with CLL. This trial utilizes two investigational drugs the anti-CD20 antibody ublituximab and TGR 1202 in comparison to the combination of two FDA approved drugs Obinutuzumab and Chlorambucil. There are four treatments arms in this study.

Patients enrolling in these trials, which are being conducted in multiple sites across the world, must meet specific criteria.

“These trials will allow our patients to obtain treatment closer to home while receiving a novel therapy,” Dr. Thomas, the principal investigator at Memorial, explains. “We will observe the patient’s condition and measure progression-free survival closely while they are on these treatment protocols for CLL.”

For more information on the studies or to inquire about eligibility for enrollment, call (401) 226-0605. Co-investigators on the Memorial team are Iole Ribizzi-Akhtar, MD, and Sabrina Witherby, MD. All are accepting new patients at The Cancer Center at Memorial Hospital. To find out more, call (401) 729-2700.

Return to News